{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:30:05Z","timestamp":1784248205231,"version":"3.55.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:p>This Clinical Insights discusses factors clinicians should consider when prescribing denosumab among postmenopausal women with osteoporosis.<\/jats:p>","DOI":"10.1001\/jamainternmed.2025.1488","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:00:46Z","timestamp":1748358046000},"page":"876","source":"Crossref","is-referenced-by-count":4,"title":["Denosumab and Fracture Prevention in Primary Care Practice"],"prefix":"10.1001","volume":"185","author":[{"given":"Douglas C.","family":"Bauer","sequence":"first","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine E.","family":"Ensrud","sequence":"additional","affiliation":[{"name":"University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"iit250003r1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians.","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann Intern Med"},{"issue":"1","key":"iit250003r2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"iit250003r3","doi-asserted-by":"publisher","author":"Everhart","journal-title":"J Clin Endocrinol Metab","DOI":"10.1210\/clinem\/dgae840"},{"issue":"9","key":"iit250003r4","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s00198-019-05051-1","article-title":"Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.","volume":"30","author":"Ban","year":"2019","journal-title":"Osteoporos Int"},{"issue":"2","key":"iit250003r5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M22-0684","article-title":"Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians.","volume":"176","author":"Ayers","year":"2023","journal-title":"Ann Intern Med"},{"issue":"3","key":"iit250003r6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture prevention with infrequent zoledronate in women 50 to 60 years of age.","volume":"392","author":"Bolland","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"iit250003r7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"iit250003r8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","article-title":"Denosumab discontinuation.","volume":"21","author":"S\u00f8lling","year":"2023","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"iit250003r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"issue":"1","key":"iit250003r10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.7326\/M24-0013","article-title":"The effect of denosumab on risk for emergently treated hypocalcemia by stage of chronic kidney disease: a target trial emulation.","volume":"178","author":"Bird","year":"2025","journal-title":"Ann Intern Med"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2834322\/jamainternal_bauer_2025_it_250003_1751563255.33999.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T15:00:38Z","timestamp":1751900438000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2834322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.1488","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}